Diabetes mellitus Type 2 - The new face of an old lady

Swiss Medical Weekly

Volumn 142, Issue JULY, 2012, Pages

  Timper, Katharina ^a   Donath, Marc Y ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SALICYLIC ACID; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT;

ACANTHOSIS NIGRICANS; ADD ON THERAPY; BARIATRIC SURGERY; BLADDER CANCER; BLOOD GLUCOSE MONITORING; BODY MASS; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; FOOD INTAKE; GENETIC PREDISPOSITION; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE SYSTEM; IMMUNOMODULATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPOTOXICITY; LOW DRUG DOSE; MEDICAL HISTORY; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; OVERNUTRITION; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PREGNANCY DIABETES MELLITUS; REMISSION; RISK FACTOR; SMOKING CESSATION; WEIGHT REDUCTION; BODY WEIGHT; DIET; DRUG ANTAGONISM; EXERCISE; LIFESTYLE; REVIEW;

ANTI-INFLAMMATORY AGENTS; BARIATRIC SURGERY; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84864573028     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13635     Document Type: Note

References (63)

1. Dobson M. Nature of the urine in diabetes. Med Obs Inqu. 1776;5:298-310.
2. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011;34:e61-99.
3. Major RH. A history of Medicine (Blackwell Scientific, Oxford, UK) 1954;1:74-91.
4. Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 1998;92:593-6. (Pubitemid 28141507)
5. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. 2005;307:380-4. (Pubitemid 40139973)
6. Robertson RP. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes. 2004;53:633-44. (Pubitemid 38270632)
7. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16-21. (Pubitemid 39564517)
8. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116:1802-12. (Pubitemid 44033300)
9. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Meta. 2004;89:3629-43. (Pubitemid 39071447)
10. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes. 2002;51(Suppl 3):S455-61. (Pubitemid 35403430)
11. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8:923-34.
12. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med. (Berl) 2003;81:455-70. (Pubitemid 37070198)
13. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch Physiol Biochem. 2009;115:240-7.
14. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31(Suppl 2):S161-4.
15. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 2010;11:897-904.
16. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care. 2008;31:340-6. (Pubitemid 351213348)
17. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62-9.
18. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327-34.
19. Timper K, Holber A, Beyrau R, Meienberg F. Fallstricke bei der Bestimmung von HbA1c. Swiss Medical Forum. 2012(23);12:466-9.
20. Stettler C, Mueller B, Diem P. What you always wanted to know about HbA1c. Schweiz Med Wochenschr. 2000;130:993-1005. (Pubitemid 30436343)
21. American Diabetes A. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35(Suppl 1):S11-63.
22. Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33:1665-73.
23. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, et al. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes. 2004;53:160-5. (Pubitemid 38044710)
24. The prevalence of retinopathy in impaired glucose tolerance and recentonset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137-44.
25. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-40. (Pubitemid 29056916)
26. Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care. 2010;33:2211-6.
27. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999;354:617-21.
28. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800-11.
29. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34(Suppl 1):S11-61.
30. Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia. 2008;51:921-5.
31. Shah ND, Mullan RJ, Breslin M, Yawn BP, Ting HH, et al. Translating comparative effectiveness into practice: the case of diabetes medications. Med Care. 2010;48:S153-8.
32. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753-9. (Pubitemid 46354366)
33. (Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.
34. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
35. Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144:485-95. (Pubitemid 46780671)
36. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22:331-9. (Pubitemid 37254901)
37. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27:2067-73. (Pubitemid 38989258)
38. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17:1481-9.
39. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
40. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9: e1001204.
41. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
42. Sanders LJ. From Thebes to Toronto and the 21st Century: An Incredible Journey. Diabetes Spectrum. 2002;15:56-60.
43. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136-42.
44. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32-43. (Pubitemid 46046470)
45. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-24.
46. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-33.
47. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015-22.
48. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-62.
49. Bristol-Myers Squibb A. (2011) U.S. Food and Drug Administration Endocrinologic & Metabolic Advisory Committee Background Document: Dapagliflozin, BMS-512148, NDA 202293. Princeton, NJ: Bristol-Myers Squibb. pp. 1-224.
50. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-50; discussion 350-32.
51. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-56 e245.
52. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-84; discussion 484-465.
53. Pournaras DJ, le Roux CW. Obesity, gut hormones, and bariatric surgery. World J Surg. 2009;33:1983-8.
54. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-85. (Pubitemid 352008510)
55. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621-32; discussion 632-625.
56. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.
57. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91. (Pubitemid 23036092)
58. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-30. (Pubitemid 38063705)
59. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183-90. (Pubitemid 40321354)
60. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, et al. Metabolic and vascular effects of tumor necrosis factoralpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42:517-25. (Pubitemid 41527607)
61. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26. (Pubitemid 46588416)
62. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289-94. (Pubitemid 351213338)
63. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, et al. (2012) Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. In press for July 2012.